Feasibility and Safety of Local Treatment with Recombinant Human Tissue Factor Pathway Inhibitor in a Rat Model of Streptococcus pneumoniae Pneumonia
Fig 2
Nebulization with rh-TFPI attenuates coagulation in BALF but not in plasma.
Levels of thrombin-antithrombin complexes (TATc) (A), antithrombin activity (AT) (B), fibrin degradation products (FDP) (C) measured in BALF, and levels of TATc measured in plasma (D) of rats nebulized with rh-TFPI (SP rh-TFPI, open bars) or vehicle (SP control, black bars) 42 hours after intratracheal instillation of S. pneumoniae and in naïve control rats (control, grey bars). Bars depict median ± IQR; **p < 0.01 versus SP control, ##p < 0.01 versus naïve controls.